BioMarin Pharmaceuticals Inc (BMRN) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and o...
BioMarin Pharmaceuticals Inc's revenue increased 12.9% year over year, from $2.85B to $3.22B.
Net income decreased 18.3% over the same period, from $426.9M to $348.9M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 188% in total.
Operating cash flow grew 44.5% to $828.0M.
BioMarin Pharmaceuticals Inc maintains a healthy net profit margin of 10.8%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $712.0M+9.7% | $107.2M | $581.6M | $120.5M | $118.8M | $7.07B | N/A | $5.29B |
| Q3 FY2024 | $745.7M+4.7% | $106.1M | $557.3M | $113.9M | $221.5M | $6.85B | N/A | $5.41B |
| Q4 FY2024 | $747.3M+0.2% | $124.9M | $611.2M | $161.4M | $185.6M | $6.99B | N/A | $5.66B |
| Q1 FY2025 | $745.1M-0.3% | $185.7M | $593.6M | $223.9M | $174.4M | $7.15B | N/A | $5.79B |
| Q2 FY2025 | $825.4M+10.8% | $240.5M | $675.3M | $276.9M | $185.3M | $7.46B | N/A | $6.03B |
| Q3 FY2025 | $776.1M-6.0% | $-30.7M | $636.0M | $-46.7M | $368.7M | $7.61B | N/A | $6.06B |
| Q4 FY2025 | $874.6M+12.7% | $-46.6M | $598.9M | $-44.6M | $99.6M | $7.59B | N/A | $6.09B |
| Q1 FY2026 | $766.2M-12.4% | $105.5M | $571.2M | $129.6M | $220.7M | $8.59B | $1.43B | $6.21B |
Balance Sheet Summary (Latest Period)
BioMarin Pharmaceuticals Inc (BMRN) Financial Statements & Revenue History
BioMarin Pharmaceuticals Inc (BMRN) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $63.89 with a market capitalization of $12. This page provides 41 historical financial statements for BioMarin Pharmaceuticals Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, BioMarin Pharmaceuticals Inc reported revenue of $3.2 billion, representing 12.9% year-over-year growth. The net profit margin of 10.8% indicates moderate profitability..
BMRN Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows BioMarin Pharmaceuticals Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BMRN is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BMRN's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently BioMarin Pharmaceuticals Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BMRN's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BMRN Financial Data
Investors use BioMarin Pharmaceuticals Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BMRN's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BMRN's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BMRN's financial health score, earnings, and pre-market pricing.
Financial data is sourced from BioMarin Pharmaceuticals Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BMRN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.